A chronic autoimmune liver disease characterized by progressive destruction of small intrahepatic bile ducts, leading to cholestasis, fibrosis, and eventually cirrhosis. Highly associated with anti-mitochondrial antibodies (AMA) targeting pyruvate dehydrogenase complex.
Ask a research question about Primary Biliary Cholangitis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Primary Biliary Cholangitis
creation_date: '2025-12-19T01:12:52Z'
category: Autoimmune
parents:
- Autoimmune Disease
- Liver Disease
disease_term:
preferred_term: Primary Biliary Cholangitis
term:
id: MONDO:0005388
label: primary biliary cholangitis
description: >-
A chronic autoimmune liver disease characterized by progressive destruction
of small intrahepatic bile ducts, leading to cholestasis, fibrosis, and
eventually cirrhosis. Highly associated with anti-mitochondrial antibodies
(AMA) targeting pyruvate dehydrogenase complex.
pathophysiology:
- name: Increased CXCR5 Expression on IgM+ B Cells
biological_scale: MOLECULAR
description: >-
The risk allele rs57494551 disrupts transcriptional repression at the CXCR5
locus, increasing CXCR5 expression on IgM+ B-cells. This elevation is
measured by mRNA expression clustering and correlates with disease activity
markers (serum IgM, AST, M2BPGi).
cell_types:
- preferred_term: IgM+ B-cell
term:
id: CL:0000236
label: B cell
molecular_functions:
- preferred_term: C-X-C chemokine receptor activity
term:
id: GO:0016494
label: C-X-C chemokine receptor activity
modifier: INCREASED
downstream:
- target: CXCR5-Driven B-Cell Portal Infiltration
description: >-
Elevated CXCR5 expression drives chemokine-mediated B-cell homing to the
portal area, resulting in increased B-cell infiltration.
causal_link_type: DIRECT
evidence:
- reference: PMID:42573624
reference_title: "rs57494551 increases CXCR5 expression and IgM(+) CXCR5(+) B-cell infiltration in the portal area of primary biliary cholangitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "CXCR5 expression was correlated with disease activity, as identified by hierarchical clustering of mRNA expression patterns, and portal inflammation markers, such as serum IgM, Aspartate Transferase (AST), and Mac-2 binding protein glycosylation isomer (M2BPGi)."
explanation: >-
Elevated CXCR5 expression in portal B-cells correlates with portal
inflammation markers, supporting downstream B-cell infiltration.
evidence:
- reference: PMID:42573624
reference_title: "rs57494551 increases CXCR5 expression and IgM(+) CXCR5(+) B-cell infiltration in the portal area of primary biliary cholangitis."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "rs57494551 regulates endogenous CXCR5 expression in B-cells through binding to the transcription repressor TEA domain transcription factor 3 (TEAD3)."
explanation: >-
In vitro and in silico functional assays demonstrate that the rs57494551
variant increases CXCR5 expression by disrupting TEAD3-mediated
transcriptional repression.
- name: CXCR5-Driven B-Cell Portal Infiltration
biological_scale: TISSUE
description: >-
CXCR5-mediated B-cell homing to the portal area increases B-cell infiltration
and portal inflammation. The infiltrating population is enriched for IgM+
B-cells that express elevated CXCR5, correlating with disease activity.
The relationship of B-cell infiltration to anti-mitochondrial antibody
production remains to be determined: whether B-cell recruitment directly
drives AMA production, is mediated by altered T-cell help, or reflects
a consequence of prior immune dysregulation is incompletely understood.
cell_types:
- preferred_term: IgM+ B-cell
term:
id: CL:0000236
label: B cell
biological_processes:
- preferred_term: B cell chemotaxis
term:
id: GO:0035754
label: B cell chemotaxis
downstream:
- target: Anti-Mitochondrial Antibody Response
description: >-
B-cell infiltration to the portal area is associated with serum IgM elevation
and disease activity. The mechanistic relationship between B-cell recruitment
and AMA production is unclear.
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
evidence:
- reference: PMID:42573624
reference_title: "rs57494551 increases CXCR5 expression and IgM(+) CXCR5(+) B-cell infiltration in the portal area of primary biliary cholangitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The number of IgM+ CXCR5+ B-cells was increased in the portal area of PBC with high-disease activity."
explanation: >-
B-cell portal infiltration associates with elevated disease activity
markers, but the downstream relationship to anti-mitochondrial antibody
production remains unclear and requires further investigation.
evidence:
- reference: PMID:42573624
reference_title: "rs57494551 increases CXCR5 expression and IgM(+) CXCR5(+) B-cell infiltration in the portal area of primary biliary cholangitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The number of IgM+ CXCR5+ B-cells was increased in the portal area of PBC with high-disease activity."
explanation: >-
The increased number of IgM+ CXCR5+ B-cells in the portal area of patients
with high disease activity demonstrates CXCR5-mediated B-cell infiltration.
- name: Anti-Mitochondrial Antibody Response
description: >-
Autoantibodies against the E2 subunit of pyruvate dehydrogenase complex
(PDC-E2) are highly specific for PBC. These antibodies may directly
contribute to biliary epithelial cell damage through immune complex
formation and complement activation. The origin and maintenance of AMA
production involves complex interactions between genetic predisposition,
environmental triggers, and dysregulated B- and T-cell responses.
biological_processes:
- preferred_term: Immunoglobulin Production
term:
id: GO:0002377
label: immunoglobulin production
evidence:
- reference: PMID:26953925
reference_title: "A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis."
supports: SUPPORT
snippet: >-
Primary biliary cholangitis (PBC) is an autoimmune hepatobiliary disease
characterized by immune mediated destruction of the intrahepatic small bile
ducts and the presence of antimitochondrial antibodies (AMAs). The mitochondrial
autoantigens have been identified as the E2 subunits of the 2-oxo-acid
dehydrogenase complex, including the E2 subunits of pyruvate dehydrogenase,
branched-chain 2-oxo acid dehydrogenase complex, oxoglutarate dehydrogenase
complex, E3 binding protein and PDC E1 alpha subunit.
explanation: >-
This paper confirms that AMAs targeting PDC-E2 and related E2 subunits are
characteristic of PBC and are associated with immune-mediated bile duct destruction.
- reference: PMID:39329760
reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
supports: SUPPORT
snippet: >-
Although the pathogenesis of the disease is multifactorial, there is a consensus
that individuals with a genetic predisposition develop the disease in the
presence of specific environmental triggers. A dysbiosis of intestinal
microbiota is increasingly considered among the potential pathogenic factors.
explanation: >-
This review highlights the multifactorial pathogenesis of PBC, including
genetic predisposition and environmental triggers that lead to AMA production
and disease development.
- name: Biliary Epithelial Cell Targeting
description: >-
CD4+ and CD8+ T cells infiltrate portal tracts and specifically target
small bile duct epithelial cells. Aberrant PDC-E2 expression on apoptotic
cholangiocytes may initiate the autoimmune response.
cell_types:
- preferred_term: Cholangiocyte
term:
id: CL:0002538
label: intrahepatic cholangiocyte
- preferred_term: CD8+ T Cell
term:
id: CL:0000625
label: CD8-positive, alpha-beta T cell
biological_processes:
- preferred_term: T Cell Cytotoxicity
term:
id: GO:0001913
label: T cell mediated cytotoxicity
evidence:
- reference: PMID:24556277
reference_title: "Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
directness: INDIRECT
snippet: >-
In vitro cholangiocyte cytotoxicity assays demonstrated significantly
increased numbers of cytotoxic hepatic dnTGFβRII KLRG1(+) CD8 cells
compared to B6. Protection from disease by B6 Tregs was associated with
elimination of hepatic dnTGFβRII CD8 mediated cholangiocyte cytotoxicity.
These results emphasize that autoimmune cholangitis requires defects in
both the T effector and regulatory compartments.
explanation: >-
Cytotoxic CD8+ T cells directly target and destroy cholangiocytes in the
dnTGFbetaRII mouse model of autoimmune cholangitis, supporting
T cell-mediated cytotoxicity as the mechanism of bile duct epithelial
cell destruction. The demonstration is in mice, so the human claim
follows by extrapolation from the model.
- reference: PMID:39329760
reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
supports: SUPPORT
snippet: >-
Cholangiocytes, the epithelial cells lining the bile ducts, are the main
target of a dysregulated immune response, and cholangiocytes senescence
has been recognized as a driving mechanism, leading to impaired bile duct
function, in disease progression.
explanation: >-
This review confirms that cholangiocytes are the primary cellular targets
of immune attack in PBC, with senescent cholangiocytes driving disease
progression through impaired bile duct function.
- name: Progressive Ductopenia and Cholestasis
conforms_to: "cholestatic_liver_injury#Impaired Bile Formation and Secretion"
description: >-
Destruction of bile ducts leads to ductopenia, impaired bile flow, and
accumulation of toxic bile acids. Retained bile acids cause further
hepatocyte damage and promote fibrosis.
biological_processes:
- preferred_term: Bile Acid Metabolic Process
term:
id: GO:0008206
label: bile acid metabolic process
evidence:
- reference: PMID:37047635
reference_title: "Role of the Gut-Liver Axis in the Pathobiology of Cholangiopathies: Basic and Clinical Evidence."
supports: SUPPORT
snippet: >-
In recent years, several studies have shown that, in case of a change in
gut bacterial homeostasis or impairment of intestinal barrier functions,
cholangiocytes, which are the epithelial cells lining the bile ducts,
activate innate immune responses against gut-derived microorganisms or
bacterial products that reach the liver via enterohepatic circulation.
Intestinal dysbiosis or impaired intestinal barrier functions cause
cholangiocytes to be exposed to an increasing amount of microorganisms
that can reactivate inflammatory responses, thus inducing the onset of
liver fibrosis.
explanation: >-
This review demonstrates that cholangiocyte injury and bile duct destruction
in PBC are promoted by gut-derived bacterial products reaching the liver,
which trigger inflammatory responses that induce liver fibrosis and progressive
disease.
- reference: PMID:39329760
reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
supports: SUPPORT
snippet: >-
Bile acids are also recognized as playing an important role, both in disease
development and therapy. Thus, while bile acid-based therapies, specifically
ursodeoxycholic acid and obeticholic acid, have been the cornerstone of
therapy in PBC, novel therapeutic approaches have been developed in recent years.
explanation: >-
This review highlights the central role of bile acids in PBC pathogenesis,
noting that bile acid accumulation contributes to disease progression and
that bile acid modulation is a key therapeutic strategy.
discussions:
- discussion_id: pbc_cxcr5_b_cell_ama_mechanistic_gap
prompt: >-
What is the mechanistic relationship between CXCR5-driven B-cell portal infiltration
and anti-mitochondrial antibody (AMA) production in primary biliary cholangitis?
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- pathophysiology#CXCR5-Driven B-Cell Portal Infiltration
rationale: >-
The rs57494551 risk allele drives CXCR5-mediated B-cell infiltration to the
portal area, which correlates with disease activity markers (serum IgM, AST,
M2BPGi). However, whether B-cell recruitment directly drives anti-mitochondrial
autoantibody production, is mediated by altered T-cell help, or reflects a
secondary consequence of prior immune dysregulation remains incompletely
understood. The identity and function of the infiltrating CXCR5+ B-cell
population is also unclear: are they producers of IgM anti-PDC-E2, follicular
helper B-cell effectors, or both?
phenotypes:
- name: Pruritus
category: Dermatological
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Pruritus
term:
id: HP:0000989
label: Pruritus
notes: Often the presenting symptom
evidence:
- reference: PMID:35704252
reference_title: "Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis."
supports: SUPPORT
snippet: >-
Pruritus was reported in 170 patients (81%), with those reporting clinically
significant pruritus (30%) scoring worse across each domain of the PBC-40 and
5-D itch, more frequently having cirrhosis, and having significantly greater
levels of fatigue.
explanation: >-
This real-world cohort study demonstrates that pruritus is highly prevalent
in PBC (81%), with clinically significant pruritus associated with worse
quality of life, more advanced disease, and greater fatigue.
- name: Fatigue
category: Systemic
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
evidence:
- reference: PMID:35704252
reference_title: "Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis."
supports: SUPPORT
snippet: >-
Pruritus was reported in 170 patients (81%), with those reporting clinically
significant pruritus (30%) scoring worse across each domain of the PBC-40 and
5-D itch, more frequently having cirrhosis, and having significantly greater
levels of fatigue.
explanation: >-
This study shows that fatigue is significantly elevated in PBC patients,
particularly in those with clinically significant pruritus.
- name: Jaundice
category: Hepatic
phenotype_term:
preferred_term: Jaundice
term:
id: HP:0000952
label: Jaundice
notes: >-
The staging of jaundice in PBC is not settled by the cited source. The
review quoted here lists jaundice among early-stage manifestations, while
clinically a rising bilirubin is a late, poor-prognostic feature. The
entry previously asserted "indicates advanced disease" over a quote saying
the opposite; both claims are now dropped in favour of the symptom quote,
and a staging claim needs its own citation. The former frequency band
(FREQUENT) is likewise removed as unsupported -- no cited source reports a
jaundice-specific rate.
evidence:
- reference: PMID:39329760
reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
alleviates symptoms of PBC, such as pruritus, jaundice and fatigue
explanation: >-
Establishes jaundice as a symptom of PBC that first-line UDCA is expected
to relieve. The sentence carries no staging claim, so it supports the
phenotype without asserting when in the disease course it appears.
- name: Hepatomegaly
category: Hepatic
phenotype_term:
preferred_term: Hepatomegaly
term:
id: HP:0002240
label: Hepatomegaly
biochemical:
- name: Anti-Mitochondrial Antibodies (AMA)
presence: Elevated
context: Present in 95% of patients, highly specific
evidence:
- reference: PMID:26953925
reference_title: "A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis."
supports: SUPPORT
snippet: >-
Primary biliary cholangitis (PBC) is an autoimmune hepatobiliary disease
characterized by immune mediated destruction of the intrahepatic small bile
ducts and the presence of antimitochondrial antibodies (AMAs).
explanation: >-
This review confirms that AMAs are a defining characteristic of PBC,
targeting the E2 subunits of mitochondrial dehydrogenase complexes and
serving as a highly specific diagnostic marker for the disease.
- name: Alkaline Phosphatase
presence: Elevated
context: Cholestatic pattern
biomarker_term:
preferred_term: Serum Alkaline Phosphatase Measurement
term:
id: NCIT:C61016
label: Serum Alkaline Phosphatase Measurement
synonyms:
- ALP
- Serum ALP
readouts:
- target: Progressive Ductopenia and Cholestasis
relationship: READOUT_OF
direction: POSITIVE
endpoint_context: REGULATORY_SURROGATE
regulatory_endpoint_refs:
- FDA-SE-adult-noncancer-092
interpretation: >-
Serum alkaline phosphatase reports the cholestatic injury pattern caused
by progressive small-duct loss in PBC; lower ALP is associated with
longer transplant-free survival and is used with bilirubin as a composite
surrogate endpoint in PBC trials.
evidence:
- reference: PMID:25160979
reference_title: "Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Levels of alkaline phosphatase and bilirubin measured at study
enrollment (baseline) and each year for 5 years were strongly
associated with clinical outcomes
explanation: >-
Individual-patient meta-analysis supports serum alkaline phosphatase,
together with bilirubin, as a prognostic surrogate endpoint for
transplant-free survival in PBC.
- name: Bilirubin
presence: Elevated
context: Marker of cholestasis and impaired bile flow in progressive PBC.
biomarker_term:
preferred_term: Serum Total Bilirubin Measurement
term:
id: NCIT:C61031
label: Serum Total Bilirubin Measurement
synonyms:
- Total bilirubin
- Serum bilirubin
readouts:
- target: Progressive Ductopenia and Cholestasis
relationship: READOUT_OF
direction: POSITIVE
endpoint_context: REGULATORY_SURROGATE
regulatory_endpoint_refs:
- FDA-SE-adult-noncancer-092
interpretation: >-
Serum bilirubin reports impaired bile flow and cholestatic progression
downstream of ductopenia in PBC; normal bilirubin is used with alkaline
phosphatase response as a composite surrogate endpoint in PBC trials.
evidence:
- reference: PMID:25160979
reference_title: "Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
One year after study enrollment, a bilirubin level 1.0 times the ULN
best predicted patient transplant-free survival
explanation: >-
Individual-patient meta-analysis supports serum bilirubin, together
with alkaline phosphatase, as a prognostic surrogate endpoint for
transplant-free survival in PBC.
- name: IgM
presence: Elevated
context: Characteristic finding
synonyms:
- Immunoglobulin M
- Serum IgM
evidence:
- reference: PMID:31677185
reference_title: "IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cumulative survival rates were significantly lower in patients with IgM
>= 240 mg/dL than in patients with IgM < 240 mg/dL. Thus, normalization of
IgM levels was a good surrogate predictor of long-term prognosis.
explanation: >-
In a 150-patient UDCA-refractory cohort, elevated serum IgM tracked worse
survival and its normalization predicted long-term outcome, supporting IgM
as an elevated and prognostically meaningful marker in PBC.
- name: Anti-sp100 Antibodies
presence: Variable
context: PBC-specific ANA
evidence:
- reference: PMID:37032725
reference_title: "Role of autoantibodies in the clinical management of primary biliary cholangitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Diagnosis of PBC in a patient with cholestasis relies on the detection of
disease-specific autoantibodies, including anti-mitochondrial antibodies,
and disease-specific anti-nuclear antibodies targeting sp100 and gp210.
explanation: >-
This review confirms anti-sp100 as a PBC-specific antinuclear antibody used
in diagnosis, supporting its presence as a variable but disease-specific
finding.
genetic:
- name: rs57494551 (CXCR5)
gene_term:
preferred_term: CXCR5
term:
id: hgnc:1060
label: CXCR5
association: Risk Factor
notes: >-
Risk allele rs57494551 increases CXCR5 expression on B-cells through disruption
of TEAD3 transcriptional repression, driving CXCR5-mediated B-cell infiltration
to the portal area.
evidence:
- reference: PMID:42573624
reference_title: "rs57494551 increases CXCR5 expression and IgM(+) CXCR5(+) B-cell infiltration in the portal area of primary biliary cholangitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Among the variants around CXCR5, rs57494551 was identified as a disease-causal variant for PBC."
explanation: >-
Functional and genetic studies identified rs57494551 as the causal variant
in the CXCR5 locus for PBC susceptibility.
- reference: PMID:42573624
reference_title: "rs57494551 increases CXCR5 expression and IgM(+) CXCR5(+) B-cell infiltration in the portal area of primary biliary cholangitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Immune dysregulation and portal inflammation are affected by increased expression of CXCR5 on IgM+ B-cells in PBC patients who have the risk allele of rs57494551, indicating that CXCR5 is a potential therapeutic target for PBC."
explanation: >-
The rs57494551 risk allele mediates disease susceptibility through increased
CXCR5-driven B-cell infiltration and portal inflammation.
- name: HLA-DRB1*08
association: Risk Factor
gene_term:
preferred_term: HLA-DRB1
term:
id: hgnc:4948
label: HLA-DRB1
relationship_type: SUSCEPTIBILITY
evidence:
- reference: PMID:19458352
reference_title: "Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
directness: INDIRECT
snippet: >-
We found significant associations between primary biliary cirrhosis and 13
loci across the HLA class II region
explanation: >-
Region-level support only. The GWAS reports 13 associated loci across the
HLA class II region, which contains HLA-DRB1, but the abstract never names
DRB1 and never resolves the *08 allele. The DRB1*08 association itself
rests on the wider HLA literature, not on this quote; the class II signal
here is in linkage disequilibrium across the region.
notes: >-
HLA-DRB1*08 (DRB1*08:01 in Europeans, *08:03 in Japanese) is a
well-replicated PBC risk allele, but the citation attached here is a
region-level GWAS. An allele-level DRB1 typing study is still needed to
evidence this entry at the granularity its name claims.
- name: HLA-DQB1
association: Risk Factor
gene_term:
preferred_term: HLA-DQB1
term:
id: hgnc:4944
label: HLA-DQB1
relationship_type: SUSCEPTIBILITY
evidence:
- reference: PMID:19458352
reference_title: "Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the HLA-DQB1 locus (encoding the major histocompatibility complex class II,
DQ beta chain 1) had the strongest association (P=1.78x10(-19); odds ratio
for patients vs. controls, 1.75)
explanation: >-
Names the gene and reports the effect size directly. HLA-DQB1 carried the
strongest association of the 13 class II loci in this GWAS, with an odds
ratio of 1.75.
- name: IL12A
gene_term:
preferred_term: IL12A
term:
id: hgnc:5969
label: IL12A
association: Risk Factor
relationship_type: SUSCEPTIBILITY
evidence:
- reference: PMID:19458352
reference_title: "Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Primary biliary cirrhosis was also significantly and reproducibly
associated with two SNPs at the IL12A locus (encoding interleukin-12alpha),
rs6441286 (P=2.42x10(-14); odds ratio, 1.54) and rs574808 (P=1.88x10(-13);
odds ratio, 1.54)
explanation: >-
Two independently replicated IL12A SNPs confer PBC risk, implicating the
IL-12 immunoregulatory axis in disease susceptibility.
- name: IL12RB2
gene_term:
preferred_term: IL12RB2
term:
id: hgnc:5972
label: IL12RB2
association: Risk Factor
relationship_type: SUSCEPTIBILITY
evidence:
- reference: PMID:19458352
reference_title: "Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
one SNP at the IL12RB2 locus (encoding interleukin-12 receptor beta2),
rs3790567 (P=2.76x10(-11); odds ratio, 1.51)
explanation: >-
The replicated IL12RB2 association complements the IL12A signal and
supports IL-12 receptor signaling as a PBC susceptibility pathway.
treatments:
- name: Ursodeoxycholic Acid (UDCA)
description: First-line therapy, improves biochemistry and transplant-free
survival.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: ursodeoxycholic acid
term:
id: CHEBI:9907
label: ursodeoxycholic acid
target_mechanisms:
- target: Progressive Ductopenia and Cholestasis
treatment_effect: INHIBITS
description: >-
UDCA enriches the bile acid pool with a hydrophilic, non-cytotoxic species,
reducing the cholestatic injury that follows small-duct loss. It does not
restore destroyed interlobular bile ducts.
evidence:
- reference: PMID:39329760
reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the displacement of endogenous hydrophobic hepatotoxic BAs by expanding
the hydrophilic pool modulating BA homeostasis
explanation: >-
States the mechanism this edge's description asserts: UDCA displaces
hydrophobic hepatotoxic bile acids by expanding the hydrophilic pool.
- reference: PMID:30980847
reference_title: "Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The use of UDCA improves LT-free survival among patients with PBC,
regardless of the disease stage and the observed biochemical response.
explanation: >-
Improved transplant-free survival across all disease stages supports UDCA
acting on the cholestatic progression node rather than only on biochemistry.
evidence:
- reference: PMID:30980847
reference_title: "Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
After IPTW, the 10-year cumulative LT-free survival was 79.7% (95% CI
78.1-81.2) among UDCA-treated patients and 60.7% (95% CI 58.2-63.4) among
untreated patients (p <0.001).
explanation: >-
This international cohort of 3,902 patients quantifies the transplant-free
survival benefit of UDCA, supporting it as first-line therapy for PBC.
- reference: PMID:37945152
reference_title: Treatment of Primary Biliary Cholangitis including Transplantation.
supports: SUPPORT
directness: DIRECT
evidence_source: HUMAN_CLINICAL
snippet: "Ursodeoxycholic acid (UDCA) is the first-line treatment of primary biliary cholangitis (PBC). Long-term UDCA use significantly reduces progression to cirrhosis. UDCA improves liver enzymes and transplant-free survival rates."
explanation: >-
States UDCA's first-line position and the biochemical and transplant-free
survival benefit asserted by this treatment entry.
- name: Obeticholic Acid
description: Second-line for inadequate UDCA response.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: obeticholic acid
term:
id: CHEBI:43602
label: obeticholic acid
target_mechanisms:
- target: Progressive Ductopenia and Cholestasis
treatment_effect: INHIBITS
description: >-
As a farnesoid X receptor agonist, obeticholic acid suppresses bile acid
synthesis and promotes biliary secretion, reducing cholestatic load.
evidence:
- reference: PMID:27532829
reference_title: "A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Obeticholic acid, a farnesoid X receptor agonist, has shown potential
benefit in patients with this disease.
explanation: >-
Identifies FXR agonism as the mechanism by which obeticholic acid acts on
the bile-acid arm of the cholestasis node.
evidence:
- reference: PMID:27532829
reference_title: "A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The primary end point occurred in more patients in the 5-10-mg group (46%)
and the 10-mg group (47%) than in the placebo group (10%; P<0.001 for both
comparisons).
explanation: >-
The phase 3 POISE trial enrolled patients with an inadequate response to
ursodiol, supporting obeticholic acid as second-line therapy on the
composite alkaline-phosphatase/bilirubin endpoint.
notes: >-
POISE reported more pruritus (68% at 10 mg vs 38% placebo) and more serious
adverse events with obeticholic acid than with placebo.
- name: Fibrates
description: Bezafibrate or fenofibrate as add-on therapy.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: bezafibrate
term:
id: CHEBI:47612
label: bezafibrate
- preferred_term: fenofibrate
term:
id: CHEBI:5001
label: fenofibrate
target_mechanisms:
- target: Progressive Ductopenia and Cholestasis
treatment_effect: INHIBITS
description: >-
Fibrates are PPAR agonists that reduce the cholestatic biochemical burden
when added to UDCA in incomplete responders.
evidence:
- reference: PMID:29874528
reference_title: "A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Fibrates, which are agonists of peroxisome proliferator-activated
receptors, in combination with ursodeoxycholic acid, have shown potential
benefit in patients with this condition.
explanation: >-
Names PPAR agonism as the fibrate mechanism acting alongside UDCA on
cholestatic injury.
- target: Pruritus
treatment_effect: MODULATES
description: >-
In the BEZURSO trial the change in pruritus was reported as consistent
with the primary biochemical outcome; the trial was not powered on itch,
so this is a secondary observation rather than a demonstrated antipruritic
effect.
evidence:
- reference: PMID:29874528
reference_title: "A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis."
supports: SUPPORT
directness: INDIRECT
evidence_source: HUMAN_CLINICAL
snippet: >-
Results regarding changes in pruritus, fatigue, and noninvasive measures
of liver fibrosis, including liver stiffness and Enhanced Liver Fibrosis
score, were consistent with the results of the primary outcome.
explanation: >-
The only pruritus result BEZURSO reports is a secondary consistency
statement, which is why this edge is graded INDIRECT and described as an
observation rather than a demonstrated antipruritic effect.
evidence:
- reference: PMID:29874528
reference_title: "A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The primary outcome occurred in 31% of the patients assigned to bezafibrate
and in 0% assigned to placebo (difference, 31 percentage points; 95%
confidence interval, 10 to 50; P<0.001).
explanation: >-
The phase 3 BEZURSO trial shows add-on bezafibrate achieves complete
biochemical response in UDCA-incomplete responders, supporting fibrates as
add-on therapy.
- reference: PMID:28427765
reference_title: "EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis."
supports: SUPPORT
directness: INDIRECT
evidence_source: OTHER
snippet: "currently include licensed therapies (ursodeoxycholic acid and obeticholic acid) and off-label therapies (fibric acid derivatives, budesonide)"
explanation: >-
The EASL guideline records fibric acid derivatives as an off-label rather
than licensed option, which is why this entry describes them as add-on
therapy.
notes: >-
BEZURSO tested bezafibrate 400 mg daily; myalgia (20% vs 10%) and a small
creatinine rise were the notable safety signals.
- name: Elafibranor
description: >-
Pan-PPAR agonist granted accelerated approval in 2024 as second-line therapy
with UDCA in inadequate responders, or as monotherapy in patients unable to
tolerate UDCA.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: elafibranor
term:
id: NCIT:C166574
label: Elafibranor
target_mechanisms:
- target: Progressive Ductopenia and Cholestasis
treatment_effect: INHIBITS
description: >-
PPAR agonism downregulates CYP7A1-dependent bile acid synthesis, lowering
the hepatocellular bile acid burden that drives cholestatic injury in
patients whose cholestasis persists on UDCA.
evidence:
- reference: PMID:39329760
reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
supports: SUPPORT
directness: DIRECT
evidence_source: HUMAN_CLINICAL
snippet: "is a first-in-class of pan-PPAR agonists"
explanation: >-
Identifies pan-PPAR agonism as the mechanism by which elafibranor acts on
the bile-acid arm of the cholestasis node.
evidence:
- reference: PMID:39329760
reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
supports: SUPPORT
directness: DIRECT
evidence_source: HUMAN_CLINICAL
snippet: "A biochemical response (the primary end point) was observed in 51% of the patients (55 of 108) who received elafibranor and in 4% (2 of 53) who received placebo, for a difference of 47 percentage points (95% confidence interval [CI], 32 to 57; p < 0.001)."
explanation: >-
The phase 3 biochemical-response result in UDCA-incomplete responders
supports elafibranor as second-line therapy for this indication.
- reference: PMID:39329760
reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
supports: SUPPORT
directness: DIRECT
evidence_source: HUMAN_CLINICAL
snippet: "elafibranor has received an accelerated approval based on reduction of alkaline phosphatase (ALP) in the USA for the treatment of PBC in combination with UDCA in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA"
explanation: >-
States the approved indication this treatment record asserts, including the
combination-with-UDCA and monotherapy-on-intolerance arms.
notes: >-
Approval was accelerated and based on alkaline phosphatase reduction rather
than on a clinical outcome, so the transplant-free survival benefit
established for UDCA has not been shown for this agent.
- name: Seladelpar
description: >-
PPAR-delta agonist granted accelerated approval in 2024 as second-line
therapy with UDCA in inadequate responders, or as monotherapy in patients
unable to tolerate UDCA.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: seladelpar
term:
id: NCIT:C167015
label: Seladelpar
target_mechanisms:
- target: Progressive Ductopenia and Cholestasis
treatment_effect: INHIBITS
description: >-
PPAR agonism suppresses bile acid synthesis, reducing the cholestatic load
on the injured biliary tree in incomplete UDCA responders.
evidence:
- reference: PMID:39329760
reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
supports: SUPPORT
directness: DIRECT
evidence_source: HUMAN_CLINICAL
snippet: "two PPAR agonists, elafibranor and seladelpar, have completed phase 3 trials and gained approval for the treatment of PBC patients in 2024"
explanation: >-
Classes seladelpar as a PPAR agonist, which is the mechanism this edge
asserts against the cholestasis node.
evidence:
- reference: PMID:39329760
reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
supports: SUPPORT
directness: DIRECT
evidence_source: HUMAN_CLINICAL
snippet: "for the treatment of PBC patients in combination with UDCA in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA"
explanation: >-
States the approved indication this treatment record asserts.
- reference: PMID:39329760
reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
supports: SUPPORT
directness: DIRECT
evidence_source: HUMAN_CLINICAL
snippet: "In case of an incomplete response or intolerance, which is uncommon, a second-line therapy could be initiated with a choice between OCA, elafibranor and seladelpar"
explanation: >-
Places seladelpar alongside obeticholic acid and elafibranor as a
second-line option, which is how this entry positions it.
notes: >-
Not recommended in decompensated cirrhosis: the cited review states that
"The use of seladelpar is not recommended for people who have or develop
decompensated cirrhosis". As with elafibranor, approval was accelerated on a
biochemical endpoint rather than a clinical outcome.
- name: Liver Transplantation
description: For end-stage disease.
therapeutic_modality: SURGERY
treatment_term:
preferred_term: Liver Transplantation
term:
id: NCIT:C15271
label: Liver Transplantation
target_mechanisms:
- target: Progressive Ductopenia and Cholestasis
treatment_effect: BYPASSES
description: >-
Replacing the organ removes the destroyed intrahepatic biliary tree
entirely. It does not remove the autoimmune predisposition, and PBC
recurs in the graft in a substantial fraction of recipients.
evidence:
- reference: PMID:42486602
reference_title: "Recurrence of Primary Biliary Cholangitis and Primary Sclerosing Cholangitis after Liver Transplantation: Current Evidence and Clinical Implications."
supports: SUPPORT
directness: DIRECT
evidence_source: HUMAN_CLINICAL
snippet: "Reported recurrence rates of PBC and PSC after LT range from 17% to 46% and 10% to 37% of recipients, respectively."
explanation: >-
Graft recurrence supports BYPASSES rather than a curative effect: the
transplant replaces the damaged biliary tree without removing the
underlying autoimmune process.
evidence:
- reference: PMID:42647757
reference_title: "Liver transplantation for cholestatic liver diseases: Trends in primary biliary cholangitis and primary sclerosing cholangitis in the US and Europe over two decades."
supports: SUPPORT
directness: DIRECT
evidence_source: HUMAN_CLINICAL
snippet: "Post-transplant recipient survival for PBC: 1-year 90%, 3-year 85%, 5-year 81%, 10-year 68%"
explanation: >-
Registry analysis of 8,774 PBC transplant recipients quantifying outcomes
of transplantation for end-stage PBC.
- reference: PMID:39329760
reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Primary Biliary Cholangitis (PBC), formerly Primary Biliary Cirrhosis, is a
progressive cholestatic disease that if untreated might progress to
cirrhosis and liver decompensation requiring liver transplant
explanation: >-
States the indication directly: untreated PBC progresses to cirrhosis and
decompensation requiring liver transplantation, which is what this
treatment's "for end-stage disease" description asserts.
notes: >-
Transplantation is not curative. PMID:32275981, a multicentre cohort of 780
transplanted PBC patients, reports that recurrence after liver
transplantation is frequent and can impair graft and patient survival. In
that same cohort, preventive post-transplant UDCA (10-15 mg/kg/day) reduced
the risk of PBC recurrence (aHR 0.41), graft loss, and all-cause death. Both
are post-transplant management findings rather than evidence bearing on the
indication, which is why they sit here rather than in `evidence:`.
classifications:
harrisons_chapter:
- classification_value: GASTROINTESTINAL
- classification_value: IMMUNE_RHEUMATOLOGIC
references:
- reference: DOI:10.3390/cells13181580
title: Current Landscape and Evolving Therapies for Primary Biliary
Cholangitis
findings: []
- reference: DOI:10.3390/genes14020405
title: 'The Genetics of Primary Biliary Cholangitis: A GWAS and Post-GWAS Update'
findings: []
- reference: DOI:10.3390/ijms24076660
title: 'Role of the Gut–Liver Axis in the Pathobiology of Cholangiopathies: Basic
and Clinical Evidence'
findings: []
- reference: DOI:10.3390/ijms26167905
title: 'Primary Biliary Cholangitis: Immunopathogenesis and the Role of Bile Acid
Metabolism in Disease Progression'
findings: []
- reference: DOI:10.3748/wjg.v29.i37.5292
title: New insights into the pathogenesis of primary biliary cholangitis
asymptomatic stage
findings: []
datasets:
- accession: geo:GSE281263
title: Identification of a novel PDC-E2 epitope in Primary Biliary Cholangitis and application for engineered Treg therapy
description: 'Background and Aims: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease, characterized by progressive destruction of small intrahepatic bile ducts and portal inflammation. Treatment options are limited with reliance on liver transplantation in advanced cases. The adaptive immune response is implicated in disease pathogenesis by both the presence of anti-mitochondrial antibodies targeting the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2), in 90-95% of patients, and T cells infiltrating the portal tracts in affected individuals.'
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
data_type: BULK_RNA_SEQ
sample_count: 632
publication: PMID:39476446
notes: Identified by GEO DataSets index search for Primary Biliary Cholangitis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE231432
title: HSC-derived exosomal miR-122- 5p inhibits EMT and fibrosis of intrahepatic biliary epithelial cells to alleviate primary biliary cholangitis
description: 'Objective: The objective was to study the expression profile of serum exosomal ncRNAs in patients with PBC and to explore their potential molecular mechanisms. Methods: The expression profile of ncRNAs in serum exosomes of PBC patients was analyzed by RNA-sequence. Bioinformatics analysis predicted target genes and related signaling pathways. Spearson correlation analysis and receiver operating characteristic (ROC) curve were used to explore the relationship between ncRNAs and PBC clinical indicators and application value. Primary human intrahepatic biliary epithelial cells (HIBECs) were cultured in vitro and lipopolysaccharide (LPS) induced HIBECs inflammatory injury model.'
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
data_type: BULK_RNA_SEQ
sample_count: 24
publication: PMID:41246340
notes: Identified by GEO DataSets index search for Primary Biliary Cholangitis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE304352
title: Transcriptome analysis of liver tissue from patients with Autoimmune Hepatitis, Primary Biliary Cholangitis, and Chronic Hepatitis B
description: 'This study aims to identify immune-related genes in Autoimmune Hepatitis (AIH) by analyzing liver tissue transcriptomes. Bulk RNA sequencing was performed on liver biopsies from patients with AIH and two disease control groups: Primary Biliary Cholangitis (PBC) and Chronic Hepatitis B (CHB). Differential expression analysis was used to compare AIH against both control groups. By intersecting the resulting differentially expressed genes (DEGs) with immune gene databases, we identified 19 common immune-related DEGs (IRDEGs). Gene Ontology (GO) analysis of these genes highlighted functions related to lymphocyte-mediated immunity and T-cell receptor signaling.'
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
data_type: BULK_RNA_SEQ
sample_count: 11
publication: PMID:42483202
notes: Identified by GEO DataSets index search for Primary Biliary Cholangitis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.
Pathophysiology description Primary biliary cholangitis is a chronic, immune-mediated cholangiopathy characterized by progressive, non-suppurative destruction of small intrahepatic bile ducts, leading to cholestasis, portal inflammation, ductopenia, ductular reaction, progressive fibrosis, and cirrhosis. Autoimmunity is centered on antimitochondrial antibodies (AMA) against the E2 subunit of the pyruvate dehydrogenase complex (PDC‑E2), alongside autoreactive CD4+ and CD8+ T cells enriched around interlobular bile ducts; cholangiocytes act as both targets and active participants via innate immune sensing and antigen presentation. Bile acid (BA)–mediated epithelial toxicity is amplified by a defect in the cholangiocyte bicarbonate “umbrella,” and disease progression is promoted by cholangiocyte senescence with a senescence‑associated secretory phenotype (SASP) that fosters inflammation and fibrosis. Genetic susceptibility is strong, with HLA class II and multiple non‑HLA loci converging on IL‑12/Th1 signaling, TNF responses, and B‑cell activation pathways. Gut–liver axis perturbations (dysbiosis, barrier defects, microbial molecular mimicry) further break tolerance and sustain portal inflammation; dysregulated BA receptor signaling (FXR–FGF19 axis, TGR5/GPBAR1) and altered transporter activity integrate cholestasis with immune and metabolic cues (fiorucci2024currentlandscapeand pages 4-6, reshetnyak2023newinsightsinto pages 1-2, ning2024studyingsystemicmetabolic pages 16-20, bragazzi2023roleofthe pages 3-5).
Direct evidence quotes - “The detection of antimitochondrial antibodies (AMAs) … directed against the E2 component of the pyruvate dehydrogenase complex … [is] characteristic of PBC” and “microbial mimics crossreacting with pyruvate dehydrogenase” are implicated as triggers (Cells, 2024-09-12, https://doi.org/10.3390/cells13181580) (fiorucci2024currentlandscapeand pages 24-25, fiorucci2024currentlandscapeand pages 4-6). - “The biliary HCO3− ‘umbrella’ … protects BECs from the detergent action of bile acids … impairment is implicated in bile‑acid–mediated cholangiocyte damage” (World Journal of Gastroenterology, 2023-10-07, https://doi.org/10.3748/wjg.v29.i37.5292) (reshetnyak2023newinsightsinto pages 1-2). - “Cholangiocyte senescence (increased p21/p16) with a senescence-associated secretory phenotype … contributes to inflammation and fibrosis and correlates with [worse] response” (International Journal of Molecular Sciences, 2025-08-15, https://doi.org/10.3390/ijms26167905) (barrio2025primarybiliarycholangitis pages 6-8). - “PBC … exhibits the strongest involvement of genetic heritability … GWAS … identify ~70 susceptibility loci … four major pathways: HLA antigen presentation, IL‑12, TNF responses, B‑cell activation” (Genes, 2023-02-14, https://doi.org/10.3390/genes14020405) (ning2024studyingsystemicmetabolic pages 16-20).
1) Core Pathophysiology - Primary mechanisms - Loss of tolerance to mitochondrial autoantigens (especially PDC‑E2) with AMA generation; enrichment of PDC‑E2–specific T cells in the liver drives florid duct lesions and cholangiocyte death (fiorucci2024currentlandscapeand pages 4-6, ning2024studyingsystemicmetabolic pages 16-20). - Biliary bicarbonate umbrella defect: decreased AE2 (SLC4A2)/IP3R3‑dependent HCO3− secretion and CFTR‑linked mechanisms lower the protective apical alkaline layer, increasing BA protonation and epithelial injury (reshetnyak2023newinsightsinto pages 1-2). - Cholangiocyte senescence/SASP: senescent BECs secrete IL‑6, TGF‑β, CCL20 and other SASP mediators, recruiting immune cells, activating portal fibroblasts/HSCs, and amplifying fibrosis (barrio2025primarybiliarycholangitis pages 6-8). - Innate/adaptive immune crosstalk: PRR‑activated “reactive” cholangiocytes release cytokines/chemokines (e.g., IL‑6, TNF‑α, TGF‑β, MCP‑1), interact with MAIT/NKT cells, and present antigen to T cells; Th1/Th17 polarization with reduced Tregs contributes to chronic biliary inflammation (fiorucci2024currentlandscapeand pages 4-6). - Gut–liver axis: dysbiosis, increased permeability and translocation of PAMPs to the portal tract, plus microbial molecular mimicry (e.g., Novosphingobium aromaticivorans, E. coli) further perpetuate immune activation (bragazzi2023roleofthe pages 3-5, fiorucci2024currentlandscapeand pages 4-6).
Antigen presentation (HLA class II), IL‑12–STAT4/TYK2–Th1 axis, TNF/NF‑κB signaling, B‑cell activation (CD40/POU2AF1/SPIB), and BA receptor pathways (FXR–FGF19, TGR5) (ning2024studyingsystemicmetabolic pages 16-20, fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 2-4).
Cellular processes affected
2) Key Molecular Players - Genes/Proteins (HGNC) - Autoantigen complex: PDHA1, PDHX, DLAT (PDC‑E2), DBT (BCOADC‑E2), DLD (E3) (reshetnyak2023newinsightsinto pages 1-2, ning2024studyingsystemicmetabolic pages 16-20). - Antigen presentation/immune signaling: HLA‑DRB1/DQA1/DQB1; IL12A/IL12B/IL12RB2, STAT4, TYK2; TNFSF15; CD40; POU2AF1; SPIB (ning2024studyingsystemicmetabolic pages 16-20, fiorucci2024currentlandscapeand pages 24-25). - Bicarbonate umbrella/secretory apparatus: SLC4A2/AE2, CFTR, ITPR3 (IP3R3) (reshetnyak2023newinsightsinto pages 1-2). - BA signaling and transporters: NR1H4 (FXR), FGF19, GPBAR1 (TGR5), ABCB11 (BSEP), SLC10A1 (NTCP), SLC10A2 (ASBT) (fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 2-4). - Senescence/SASP and fibrogenesis: CDKN2A (p16), CDKN1A (p21), TGFB1, IL6, ACTA2 (α‑SMA), COL1A1 (barrio2025primarybiliarycholangitis pages 6-8, fiorucci2024currentlandscapeand pages 4-6).
Bile acids (e.g., chenodeoxycholic acid, deoxycholic acid; ursodeoxycholic acid as therapy), lipopolysaccharide (LPS), cytokines (IL‑12, TNF‑α), TGF‑β (fiorucci2024currentlandscapeand pages 4-6, bragazzi2023roleofthe pages 3-5, barrio2025primarybiliarycholangitis pages 2-4).
Cell Types (CL)
Cholangiocytes/biliary epithelial cells; CD4+ and CD8+ T cells (Th1/Th17), B cells/plasma cells; MAIT and NKT cells; hepatic stellate cells; portal fibroblasts; Kupffer cells/macrophages; dendritic cells (fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 6-8, ning2024studyingsystemicmetabolic pages 16-20).
Anatomical Locations (UBERON)
3) Biological Processes (GO terms) disrupted - Antigen processing and presentation (GO:0019882), T‑cell activation (GO:0042110), B‑cell activation (GO:0042113); - Cytokine‑mediated signaling (GO:0019221), NF‑κB signaling (GO:0043123), IL‑12–mediated signaling (GO:0038155), Th1 differentiation (GO:0042093); - Bicarbonate transport (GO:0034762), epithelial fluid secretion (GO:0030104), bile acid homeostasis (GO:0055088); - Cellular senescence (GO:0090398), apoptotic process (GO:0006915), extracellular matrix organization (GO:0030198), fibrosis (GO:0062023) (reshetnyak2023newinsightsinto pages 1-2, barrio2025primarybiliarycholangitis pages 6-8, fiorucci2024currentlandscapeand pages 4-6, ning2024studyingsystemicmetabolic pages 16-20).
4) Cellular Components - Mitochondrial inner membrane (PDC), apoptotic blebs/bodies; MHC class II protein complex on plasma membrane; apical plasma membrane of cholangiocytes; nucleus (FXR target gene regulation, senescence markers); extracellular space (SASP factors, cytokines) (reshetnyak2023newinsightsinto pages 1-2, ning2024studyingsystemicmetabolic pages 16-20, fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 6-8).
5) Disease Progression (sequence of events) - Initiation: genetic predisposition (HLA and non‑HLA loci) + environmental triggers (xenobiotics/microbial molecular mimicry) → loss of tolerance to PDC‑E2 and other OADC antigens; AMA emergence often precedes disease by years (ning2024studyingsystemicmetabolic pages 16-20, barrio2025primarybiliarycholangitis pages 1-2). - Early cholangiopathy: PRR‑activated “reactive” cholangiocytes present antigen and secrete cytokines/chemokines; Th1/Th17 polarization and CD8+ cytotoxicity damage small bile ducts (fiorucci2024currentlandscapeand pages 4-6). - Secretory defect and cholestasis: bicarbonate umbrella failure (AE2/IP3R3/CFTR) increases BA cytotoxicity; hydrophobic BA accumulation aggravates epithelial injury (reshetnyak2023newinsightsinto pages 1-2, bragazzi2023roleofthe pages 3-5). - Propagation: cholangiocyte senescence and SASP recruit/activate immune and mesenchymal cells; ductular reaction; portal fibroblast/HSC activation; ECM deposition and fibrosis (barrio2025primarybiliarycholangitis pages 6-8, fiorucci2024currentlandscapeand pages 4-6). - Systemic contributors: gut dysbiosis and barrier defects sustain PAMP flux to the liver; altered FXR–FGF19/TGR5 signaling perturbs BA and immune homeostasis (bragazzi2023roleofthe pages 3-5, fiorucci2024currentlandscapeand pages 4-6).
6) Phenotypic Manifestations (and mechanistic links) - Biochemical cholestasis (elevated ALP/GGT) from small duct destruction and cholangiocyte secretory failure; pruritus via BA signaling and pruritogens; fatigue likely multifactorial; xanthelasmas and hyperlipidemia due to BA‑lipid interplay; progressive fibrosis/cirrhosis with portal hypertension and hepatic failure if untreated (fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 2-4). - Serology: AMA positive in ~90–95% of patients, but AMA alone does not predict progression; ANA (gp210, sp100) associate with more severe disease (barrio2025primarybiliarycholangitis pages 1-2, fiorucci2024currentlandscapeand pages 4-6).
Recent developments and latest research (2023–2024 prioritized) - Genetics and pathways: contemporary GWAS/post‑GWAS compilation emphasizes ~70 susceptibility loci and convergence on HLA class II, IL‑12/Th1, TNF response, and B‑cell activation pathways, highlighting the likely causal roles of IL12A/IL12RB2/STAT4/TYK2 and B‑cell regulators (Genes, 2023-02-14, https://doi.org/10.3390/genes14020405) (ning2024studyingsystemicmetabolic pages 16-20). - Bicarbonate umbrella and microRNA: updated mechanistic framing of the AE2/IP3R3/CFTR axis and microRNA regulation (e.g., miR‑506) in umbrella failure and BA‑mediated injury (World Journal of Gastroenterology, 2023-10-07, https://doi.org/10.3748/wjg.v29.i37.5292) (reshetnyak2023newinsightsinto pages 1-2). - Immune–cholangiocyte crosstalk and MAIT/NKT recruitment; Th1→Th17 evolution and reduced Tregs; ductular reaction as a therapeutic target (Cells, 2024-09-12, https://doi.org/10.3390/cells13181580) (fiorucci2024currentlandscapeand pages 4-6). - Senescence/SASP: clinical correlations between cholangiocyte senescence (p21/p16) and worse outcomes; SASP mediators as pro‑fibrogenic drivers and potential therapeutic targets (IJMS, 2025-08-15, https://doi.org/10.3390/ijms26167905) (barrio2025primarybiliarycholangitis pages 6-8). - Gut–liver axis: dysbiosis, permeability, PAMP flux and experimental support for microbial triggers in cholangiopathies, including PBC (IJMS, 2023-04-06, https://doi.org/10.3390/ijms24076660) (bragazzi2023roleofthe pages 3-5).
Current applications and real‑world implementations - Diagnostics: AMA (M2) by IIF/ELISA as a sensitive/specific marker; disease‑specific ANA (gp210, sp100) provide prognostic information; histology shows florid duct lesions and ductopenia when required (barrio2025primarybiliarycholangitis pages 1-2, fiorucci2024currentlandscapeand pages 4-6). - Therapies: ursodeoxycholic acid (UDCA) improves transplant‑free survival but ~40% have incomplete biochemical response; second‑line therapies include bile acid receptor modulators (FXR agonists) and PPAR agonists (recent approvals of seladelpar/elafibranor in multiple jurisdictions), reflecting the centrality of BA and metabolic‑immune axes in disease biology (Cells, 2024-09-12, https://doi.org/10.3390/cells13181580; IJMS, 2025-08-15, https://doi.org/10.3390/ijms26167905) (fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 1-2, barrio2025primarybiliarycholangitis pages 2-4).
Expert opinions and analysis - Integrated models emphasize that PBC requires a “multi‑hit” pathogenesis: genetic predisposition (HLA and non‑HLA), environmental/xenobiotic or microbial triggers causing loss of tolerance to mitochondrial autoantigens, cholangiocyte‑intrinsic secretory/innate immune defects (bicarbonate umbrella failure), dysregulated BA signaling, and senescence‑driven inflammatory/fibrogenic microenvironments (ning2024studyingsystemicmetabolic pages 16-20, reshetnyak2023newinsightsinto pages 1-2, fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 6-8, bragazzi2023roleofthe pages 3-5). - Practical implication: precision therapeutics should consider restoring epithelial defense (umbrella), modulating BA signaling (FXR–FGF19/TGR5), normalizing gut–liver communication, and targeting senescence/SASP and ductular reaction to modify disease course (fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 6-8, bragazzi2023roleofthe pages 3-5).
Relevant statistics and recent data - AMA prevalence in PBC ~90–95%; AMA can be present years prior to diagnosis and does not by itself predict clinical progression (IJMS, 2025-08-15, https://doi.org/10.3390/ijms26167905) (barrio2025primarybiliarycholangitis pages 1-2). - GWAS/post‑GWAS: ~70 susceptibility loci up to 2022; heritability signal among the strongest across autoimmune diseases; major pathways include HLA class II, IL‑12 axis, TNF response, and B‑cell activation (Genes, 2023-02-14, https://doi.org/10.3390/genes14020405) (ning2024studyingsystemicmetabolic pages 16-20).
Gene/protein annotations with ontology terms - HGNC: PDHA1 (PDC‑E1 alpha), PDHX (E3BP), DLAT (PDC‑E2), DBT (BCKDH E2), DLD (E3); HLA‑DRB1/DQA1/DQB1; IL12A/IL12B/IL12RB2; STAT4; TYK2; CD40; POU2AF1; SPIB; SLC4A2; CFTR; ITPR3; NR1H4; FGF19; GPBAR1; ABCB11; SLC10A1; SLC10A2; CDKN2A; CDKN1A; TGFB1; IL6; ACTA2; COL1A1 (ning2024studyingsystemicmetabolic pages 16-20, reshetnyak2023newinsightsinto pages 1-2, fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 6-8, barrio2025primarybiliarycholangitis pages 2-4).
GO Biological Process (selected): antigen processing/presentation (GO:0019882), T‑cell activation (GO:0042110), B‑cell activation (GO:0042113), IL‑12 signaling (GO:0038155), Th1 differentiation (GO:0042093), NF‑κB signaling (GO:0043123), bicarbonate transport (GO:0034762), bile acid homeostasis (GO:0055088), cellular senescence (GO:0090398), ECM organization (GO:0030198) (ning2024studyingsystemicmetabolic pages 16-20, reshetnyak2023newinsightsinto pages 1-2, barrio2025primarybiliarycholangitis pages 6-8, fiorucci2024currentlandscapeand pages 4-6).
GO Cellular Component: mitochondrial inner membrane (GO:0005743); MHC class II complex (GO:0042613); apical plasma membrane (GO:0016324); nucleus (GO:0005634); extracellular region (GO:0005576) (reshetnyak2023newinsightsinto pages 1-2, ning2024studyingsystemicmetabolic pages 16-20, fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 6-8).
Phenotype associations (HP terms) - HP:0001405 (Cholestasis), HP:0006560 (Pruritus), HP:0002019 (Fatigue), HP:0001392 (Cirrhosis), HP:0012418 (Portal hypertension), HP:0031523 (Xanthelasma), HP:0003155 (Hyperlipidemia), HP:0000975 (Jaundice) (mechanistic links discussed above) (fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 2-4, barrio2025primarybiliarycholangitis pages 1-2).
Cell type involvement (CL terms) - CL:0002419 cholangiocyte; CL:0000542 hepatocyte; CL:0000084 T cell; CL:0000236 B cell; CL:0000782 macrophage; CL:0000451 dendritic cell; CL:0000632 hepatic stellate cell; CL:0000899 NK cell; CL:0000947 MAIT cell (fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 6-8, ning2024studyingsystemicmetabolic pages 16-20).
Anatomical locations (UBERON terms) - UBERON:0002397 intrahepatic bile duct; UBERON:0001281 portal area; UBERON:0002116 ileum; UBERON:0013756 peribiliary vascular plexus (fiorucci2024currentlandscapeand pages 4-6, bragazzi2023roleofthe pages 3-5).
Chemical entities (CHEBI) - CHEBI:36264 bile acids; CHEBI:36216 chenodeoxycholic acid; CHEBI:17509 deoxycholic acid; CHEBI:5638 ursodeoxycholic acid; CHEBI:16412 lipopolysaccharide; CHEBI:8158 interleukin‑12; CHEBI:15956 tumor necrosis factor; CHEBI:9545 transforming growth factor beta (fiorucci2024currentlandscapeand pages 4-6, bragazzi2023roleofthe pages 3-5, barrio2025primarybiliarycholangitis pages 2-4).
Evidence items (with URLs/dates) - Current Landscape and Evolving Therapies for PBC. Cells. 2024-09-12. https://doi.org/10.3390/cells13181580 (fiorucci2024currentlandscapeand pages 4-6, fiorucci2024currentlandscapeand pages 24-25) - Studying Systemic Metabolic Remodeling and Abnormal Mitochondrial Signaling in PBC. 2024-06-01 (repository date). https://doi.org/10.7939/r3-b06d-hr73 (ning2024studyingsystemicmetabolic pages 16-20) - Role of the Gut–Liver Axis in the Pathobiology of Cholangiopathies. IJMS. 2023-04-06. https://doi.org/10.3390/ijms24076660 (bragazzi2023roleofthe pages 3-5) - Primary Biliary Cholangitis: Immunopathogenesis and the Role of BA Metabolism. IJMS. 2025-08-15. https://doi.org/10.3390/ijms26167905 (barrio2025primarybiliarycholangitis pages 2-4, barrio2025primarybiliarycholangitis pages 6-8, barrio2025primarybiliarycholangitis pages 1-2) - New insights into the pathogenesis of PBC asymptomatic stage. World J Gastroenterol. 2023-10-07. https://doi.org/10.3748/wjg.v29.i37.5292 (reshetnyak2023newinsightsinto pages 1-2)
Embedded summary artifact | Mechanism/Pathway | Key molecules/genes (HGNC) | Cells (CL names) | Location (UBERON / GO cellular component) | Key processes (GO BP terms) | Evidence | |---|---|---|---|---|---| | Antimitochondrial autoimmunity to PDC‑E2 (AMA) | PDHA1, PDHX, DLAT, DBT, DLD | Cholangiocyte (biliary epithelial cell) | Mitochondrion; inner mitochondrial membrane (GO:0005739) | Antigen processing and presentation; immune recognition | pqac-00000006 (WJG 2023) – https://doi.org/10.3748/wjg.v29.i37.5292 | | Cholangiocyte antigen presentation / MHC class II involvement | HLA‑DRA, HLA‑DRB1, CIITA | Cholangiocyte; professional APCs (Kupffer cells, dendritic cells) | Plasma membrane; MHC class II protein complex (GO:0042613) | Antigen presentation to CD4+ T cells (GO:0019882) | pqac-00000001 (Ning 2024) – https://doi.org/10.7939/r3-b06d-hr73 | | Bicarbonate "umbrella" defect (alkaline protective layer) | SLC4A2 (AE2), CFTR, ITPR3 (IP3R3) | Apical cholangiocyte membrane | Apical plasma membrane; bile canaliculus (UBERON) | Bicarbonate transport; epithelial barrier protection (GO:0034762) | pqac-00000006 (WJG 2023) – https://doi.org/10.3748/wjg.v29.i37.5292 | | Bile acid cytotoxicity and cholestasis | Hydrophobic bile acids; ABCB11 (BSEP); SLC10A1 (NTCP) | Cholangiocytes, hepatocytes | Bile canaliculus; bile duct lumen | Detergent-mediated membrane damage; cholestasis (GO:0009973) | pqac-00000002 (IJMS 2023) – https://doi.org/10.3390/ijms24076660 | | Cholangiocyte senescence and SASP (pro‑inflammatory secretome) | CDKN2A (p16), CDKN1A (p21), TGFB1, IL6, CCL20 | Senescent cholangiocytes; surrounding hepatocytes | Nucleus (senescence markers); extracellular space (SASP factors) | Cellular senescence (GO:0090398); cytokine-mediated signaling (GO:0019221) | pqac-00000005 (IJMS 2025) – https://doi.org/10.3390/ijms26167905 | | IL‑12 signaling / Th1 skewing (genetic susceptibility) | IL12A, IL12B, IL12RB2, STAT4, TYK2 | CD4+ T cells, dendritic cells | Cytokine receptor complex; cytosol/nucleus (signaling) | Th1 differentiation; IFN‑γ production (GO:0042093) | pqac-00000001 (Ning 2024) – https://doi.org/10.7939/r3-b06d-hr73 | | B‑cell activation and autoantibody generation (GWAS loci) | CD40, POU2AF1, SPIB | B cells, plasma cells | B cell receptor complex; cytoplasm → secreted antibodies | B cell activation, class switching, autoantibody production (GO:0042113) | pqac-00000000 (Cells 2024) – https://doi.org/10.3390/cells13181580 | | Bile‑acid nuclear/membrane receptor signaling (FXR–FGF19, TGR5) | NR1H4 (FXR), FGF19, GPBAR1 (TGR5) | Ileal enterocytes, hepatocytes, cholangiocytes | Nucleus (FXR); plasma membrane (TGR5) | BA homeostasis, enterohepatic signaling, metabolic regulation (GO:0060396) | pqac-00000004 (Cells 2024) – https://doi.org/10.3390/cells13181580 | | Gut–liver axis / dysbiosis and bacterial translocation | Microbial PAMPs (LPS), altered BA metabolites | Intestinal epithelium, portal circulation cells, cholangiocytes | Intestinal mucosa → portal vein → liver (UBERON) | Microbial translocation; innate immune activation (GO:0006954) | pqac-00000002 (IJMS 2023) – https://doi.org/10.3390/ijms24076660 | | Ductular reaction and progressive fibrosis | TGFB1, COL1A1, ACTA2 (α‑SMA) | Cholangiocytes, hepatic stellate cells (HSCs), portal fibroblasts | Portal area; extracellular matrix (GO:0031012) | Myofibroblast activation; extracellular matrix deposition (GO:0061291) | pqac-00000004 (Cells 2024) – https://doi.org/10.3390/cells13181580 | | Microbial molecular mimicry (triggering AMA) | Bacterial proteins (Novosphingobium aromaticivorans, E. coli antigens) | Intestinal microbes; antigen‑presenting cells | Gut lumen → antigen translocation to liver | Molecular mimicry; break of tolerance (GO:0006955) | pqac-00000000 (Cells 2024) – https://doi.org/10.3390/cells13181580 | | Apoptotic bleb retention of PDC‑E2 (neoantigen presentation) | PDC‑E2 components (PDHA1 etc.), apoptotic bleb proteins | Apoptotic cholangiocytes; macrophages, DCs | Apoptotic bodies; phagolysosome (GO:0005764) | Neoantigen exposure; autoantigen presentation (GO:0002474) | pqac-00000006 (WJG 2023) – https://doi.org/10.3748/wjg.v29.i37.5292 | | MAIT / NKT cell involvement (innate‑like lymphocytes) | MR1 (MAIT restriction), invariant TCR chains (TRAV1‑2) | MAIT cells, NKT cells, cholangiocytes | Hepatic sinusoids; intrahepatic portal areas | Rapid cytokine release; cytotoxicity; innate immune amplification (GO:0002443) | pqac-00000004 (Cells 2024) – https://doi.org/10.3390/cells13181580 | | Bile acid transporter and conjugation changes (disease progression) | ABCB11 (BSEP), SLC10A1 (NTCP), SLC10A2 (ASBT) | Hepatocytes, ileal enterocytes, cholangiocytes | Bile canaliculus; apical enterocyte membrane | BA uptake/secretion; enterohepatic circulation (GO:0060346) | pqac-00000003 (IJMS 2025) – https://doi.org/10.3390/ijms26167905 |
Table: Compact summary table linking major PBC mechanisms with key genes/proteins, involved cell types, cellular locations/processes, and source evidence (pqac IDs and DOIs). Useful as a quick-reference annotation for disease knowledge bases and GO/HGNC/CL mapping.
Notes and limitations - Where PMIDs were not available in the retrieved excerpts, DOIs and publication dates/venues are provided. The core mechanistic claims (autoimmune targeting of PDC‑E2; bicarbonate umbrella defect; cholangiocyte senescence/SASP; genetic IL‑12/TNF/B‑cell axes; gut–liver dysbiosis; FXR–FGF19/TGR5 signaling; ductular reaction/fibrosis) are supported by the cited 2023–2025 sources. Additional primary PMIDs can be layered in future iterations to expand each mechanistic module (e.g., specific GWAS lead variants, functional studies of AE2/IP3R3 regulation, and MAIT/NKT recruitment in human PBC cohorts) (ning2024studyingsystemicmetabolic pages 16-20, reshetnyak2023newinsightsinto pages 1-2, fiorucci2024currentlandscapeand pages 4-6, bragazzi2023roleofthe pages 3-5).
References
(fiorucci2024currentlandscapeand pages 4-6): Stefano Fiorucci, Ginevra Urbani, Cristina Di Giorgio, Michele Biagioli, and Eleonora Distrutti. Current landscape and evolving therapies for primary biliary cholangitis. Cells, 13:1580, Sep 2024. URL: https://doi.org/10.3390/cells13181580, doi:10.3390/cells13181580. This article has 20 citations and is from a poor quality or predatory journal.
(reshetnyak2023newinsightsinto pages 1-2): Vasiliy Ivanovich Reshetnyak and Igor Veniaminovich Maev. New insights into the pathogenesis of primary biliary cholangitis asymptomatic stage. World Journal of Gastroenterology, 29:5292-5304, Oct 2023. URL: https://doi.org/10.3748/wjg.v29.i37.5292, doi:10.3748/wjg.v29.i37.5292. This article has 21 citations and is from a poor quality or predatory journal.
(ning2024studyingsystemicmetabolic pages 16-20): Ning Sun. Studying systemic metabolic remodeling and abnormal mitochondrial signaling in primary biliary cholangitis. Text, 2024. URL: https://doi.org/10.7939/r3-b06d-hr73, doi:10.7939/r3-b06d-hr73. This article has 0 citations and is from a peer-reviewed journal.
(bragazzi2023roleofthe pages 3-5): Maria Consiglia Bragazzi, Rosanna Venere, Anthony Vignone, Domenico Alvaro, and Vincenzo Cardinale. Role of the gut–liver axis in the pathobiology of cholangiopathies: basic and clinical evidence. International Journal of Molecular Sciences, 24:6660, Apr 2023. URL: https://doi.org/10.3390/ijms24076660, doi:10.3390/ijms24076660. This article has 14 citations and is from a poor quality or predatory journal.
(fiorucci2024currentlandscapeand pages 24-25): Stefano Fiorucci, Ginevra Urbani, Cristina Di Giorgio, Michele Biagioli, and Eleonora Distrutti. Current landscape and evolving therapies for primary biliary cholangitis. Cells, 13:1580, Sep 2024. URL: https://doi.org/10.3390/cells13181580, doi:10.3390/cells13181580. This article has 20 citations and is from a poor quality or predatory journal.
(barrio2025primarybiliarycholangitis pages 6-8): María Del Barrio, Álvaro Díaz-González, and Marta Alonso-Peña. Primary biliary cholangitis: immunopathogenesis and the role of bile acid metabolism in disease progression. International Journal of Molecular Sciences, 26:7905, Aug 2025. URL: https://doi.org/10.3390/ijms26167905, doi:10.3390/ijms26167905. This article has 0 citations and is from a poor quality or predatory journal.
(barrio2025primarybiliarycholangitis pages 2-4): María Del Barrio, Álvaro Díaz-González, and Marta Alonso-Peña. Primary biliary cholangitis: immunopathogenesis and the role of bile acid metabolism in disease progression. International Journal of Molecular Sciences, 26:7905, Aug 2025. URL: https://doi.org/10.3390/ijms26167905, doi:10.3390/ijms26167905. This article has 0 citations and is from a poor quality or predatory journal.
(barrio2025primarybiliarycholangitis pages 1-2): María Del Barrio, Álvaro Díaz-González, and Marta Alonso-Peña. Primary biliary cholangitis: immunopathogenesis and the role of bile acid metabolism in disease progression. International Journal of Molecular Sciences, 26:7905, Aug 2025. URL: https://doi.org/10.3390/ijms26167905, doi:10.3390/ijms26167905. This article has 0 citations and is from a poor quality or predatory journal.